Anadis therapy aiming to ease travellers' paths
03 September, 2003 by Graeme O'NeillIt's a malady with many colourful names -- Montezuma's revenge, Delhi belly, the Karachi Crouch -- but traveller's diarrhoea, by any other name, has disembowelled many a costly overseas holiday or business trip.
Patent could lead to new royalty revenue: CSL
03 September, 2003 by Iain ScottA new US patent issued to CSL (ASX:CSL) and the University of Queensland over human papillomavirus (HPV) will lead to royalty revenue if drug giant Merck launches a vaccine for the virus in the US.
PanBio tips profit for 2003-04
02 September, 2003 by Melissa TrudingerQueensland-based diagnostics company PanBio (ASX:PBO) has ended the financial year with an anticipated loss, but expects the 2003-2004 year to be profitable, said chairman Ian Sandford today.
S&P raises ResMed ratings
01 September, 2003 by Iain ScottStandard & Poor's ratings services has raised its corporate credit rating on ResMed (ASX:RMD) to 'BB-' from 'B+', and raised its senior subordinated debt rating on the company to 'B' from 'B-'.
Pest solution goes back for mouse-to-mouse resuscitation
01 September, 2003 by Graeme O'NeillPlans to conduct the first contained field trial of a transgenic virus designed to prevent episodic plagues of the house mouse in the Australian wheat belt have been set back while researchers work to improve its transmission under field conditions
Gradipore's loss slightly higher than expected
29 August, 2003 by Iain ScottSydney bioseparations specialist Gradipore (ASX:GDP) has reported an operating loss for 2002-03 of AUD$16.7 million, down from an $18.5 million loss the previous year but slightly higher than the figure forecast by the company in May.
Prima touts human trials hopes for vaccine tech
29 August, 2003 by Melissa TrudingerPrima Biomed subsidiary PanVax is planning to test its DCtag adjuvant technology with an existing marketed vaccine in human clinical trials, aiming to demonstrate enhanced immunogenicity of the re-engineered vaccine compared to existing formulations.
Cancer drug trials lift Progen losses
29 August, 2003 by Graeme O'NeillResearch and development costs -- including the expense of continuing clinical trials of its promising anti-cancer drug PI-88 -- have seen Brisbane drug-development company Progen Industries (ASX:PGL, NASDAQ:PGLAF) post a net operating loss of AUD$7.8 million to June 30.
Biota reports loss with silver lining
29 August, 2003 by Graeme O'NeillMelbourne-based drug-discovery company Biota Holdings Ltd (ASX:BTA) has reported a AUD$10.3 million loss for the year to June 30, but much of the loss was due to $9.8 million in expenses incurred by its new US subsidiary Biota Inc during its first full year of operation.
AGT presents new data on obesity
28 August, 2003 by Melissa TrudingerAGT Biosciences (ASX:AGT) has presented data on a new gene linked to obesity at the International Diabetes Federation Conference in Paris.
Antisense launches Phase I MS trials
28 August, 2003 by Melissa TrudingerAntisense Therapeutics has initiated its first Phase I clinical trial for antisense inhibitor ATL1102, which is being trialled as a treatment for multiple sclerosis.
Changes down on the pharm
28 August, 2003 by Graeme O'NeillThe age of molecular farming may be the salvation of many Australian farms.
Meditech results show decreasing losses
27 August, 2003 by Melissa TrudingerMeditech Research (ASX:MRL) has announced its half-year results, reporting a decreased loss of AUD$1.06 million after tax compared to the same period last year.
Prima swooped on by Peregrine
27 August, 2003 by Jeremy TorrInvestment bank Peregrine Corporate has upped its stake in Prima BioMed to around 14 per cent on the back of a AUD$7.2 million share placement of 11.62 million ordinary shares.
Investors boost Ventracor coffers by $33.5m
27 August, 2003 by Melissa TrudingerArtificial heart company Ventracor (ASX:VCR) has taken advantage of its market popularity to raise AUD$33.75 million in an unexpected placement to institutional and sophisticated investors in Australia, Europe and Asia.
